Acromegaly

Definition


The term acromegaly derives from the Greek words "akros" (extremity) and "megas" (large), signifying the characteristic enlargement of extremities observed in affected individuals.

It is a chronic, progressive, and multi-systemic disease caused by excessive secretion of growth hormone (GH) and subsequent hepatic production of insulin-like growth factor-1 (IGF-1).


Aetiology


Primary Causes


  • The majority (95–99%) of acromegaly cases result from growth hormone (GH)-secreting somatotroph adenomas of the anterior pituitary gland. These benign tumors lead to excessive GH secretion, stimulating hepatic production of insulin-like growth factor-1 (IGF-1), which mediates the clinical manifestations of the disease.
  • Gigantism, a related condition, occurs when GH excess develops prior to the closure of epiphyseal growth plates during childhood.


Ectopic and Rare Causes


  • Rarely, acromegaly and gigantism result from ectopic secretion of GH or growth hormone-releasing hormone (GHRH) by non-pituitary tumors, including:
    • Hypothalamic tumors (e.g., gangliocytomas) that overproduce GHRH.
    • Carcinoid tumors, pancreatic islet-cell tumors, or bronchial neoplasms that secrete ectopic GHRH or GH.
  • In some cases, somatotroph hyperplasia may occur due to GHRH overproduction from neuroendocrine tumors.


Syndromic Associations


  • Acromegaly and gigantism can occasionally occur as features of syndromic conditions:
    • Multiple Endocrine Neoplasia Type I (MEN I): An autosomal-dominant disorder with pituitary adenomas as a frequent manifestation.
    • McCune-Albright Syndrome: Characterised by fibrous dysplasia, café-au-lait spots, and endocrine dysfunction.
    • Neurofibromatosis: Associated with neurocutaneous abnormalities and, in rare cases, pituitary hyperplasia or adenomas.
    • Tuberous Sclerosis: Includes a range of benign tumors in multiple organ systems.
    • Carney Complex: Presents with spotty skin pigmentation, myxomas, and endocrine tumors, including somatotroph adenomas.


Molecular and Genetic Factors


  • Several genetic mutations contribute to the development of somatotroph adenomas:
    • GNAS1 Mutation: Activating mutations in the GNAS1 gene (gsp oncogene) are found in 30–40% of somatotroph adenomas. These mutations lead to constitutive activation of the GHRH receptor, excessive adenylyl cyclase activity, somatotroph proliferation, and unregulated GH secretion.
    • Monoclonal Origin: Studies show that most pituitary adenomas are monoclonal, arising from a single mutated cell with unchecked growth potential.
    • Other Genetic Mutations: While rare, other mutations implicated in acromegaly include those associated with syndromic conditions (e.g., mutations in MEN1 or PRKAR1A genes).


Prolactin Co-Secretion


  • Approximately 30–40% of GH-secreting tumors co-secrete prolactin, either from mammosomatotroph adenomas or mixed somatotroph-lactotroph adenomas, which can lead to additional clinical features such as galactorrhea and hypogonadism.

Pathophysiology


Overview


  • The pathophysiology of acromegaly and gigantism revolves around chronic secretion of growth hormone (GH) and resultant overproduction of insulin-like growth factor 1 (IGF-1). This dysregulated GH-IGF-1 axis leads to abnormal tissue growth, metabolic disturbances, and organomegaly.

Primary Mechanism of GH/IGF-1 Excess


  • Pituitary Adenomas: Most cases (95–99%) are caused by GH-secreting somatotroph adenomas. These tumors are typically benign and arise from dysregulation of normal pituitary cell signaling pathways.
  • Tumor Subtypes: GH-secreting tumors can include acidophil adenomas, densely or sparsely granulated somatotroph adenomas, somatomammotropic adenomas, and plurihormonal adenomas.
  • Genetic Factors:
    • GNAS1 Mutation: Activating mutations in the GNAS1 gene (gsp oncogene) are observed in up to 40% of somatotroph adenomas, resulting in constitutive activation of adenylyl cyclase, elevated cyclic adenosine monophosphate (cAMP), and excessive GH secretion.
    • Loss of 11q13 Heterozygosity: Associated with increased tumor invasiveness and biologic activity.
    • Carney Complex and PRKAR1A Mutations: About 8% of Carney complex patients develop GH-secreting tumors, with mutations in the PRKAR1A tumor-suppressor gene on chromosome 17q.


Secondary Mechanisms


  • Ectopic GH or GHRH Production: Rarely, non-pituitary tumors such as bronchial carcinoids, pancreatic islet-cell tumors, or gangliocytomas produce GH or GHRH, leading to somatotroph hyperplasia or adenomatous transformation.
  • Hypothalamic GHRH Dysregulation: Tumors in the hypothalamus can dysregulate GH secretion via excessive GHRH production.
  • Disruption of Somatostatin Tone: Tumor infiltration of somatostatin pathways, as seen in rare conditions like neurofibromatosis or astrocytomas, may also drive GH hypersecretion.


Role of IGF-1


  • IGF-1 is the primary mediator of GH's growth-promoting effects and is produced mainly in hepatocytes.
  • Chronic elevation of IGF-1 levels leads to somatic overgrowth, including acral enlargement, visceral organ hypertrophy, and metabolic dysregulation such as insulin resistance and diabetes.


Pathologic Effects of GH/IGF-1 Excess


  • Tissue Overgrowth: Includes macrognathia, frontal bossing, and enlargement of hands, feet, and visceral organs (e.g., heart, liver, and thyroid).
  • Metabolic Abnormalities: GH-induced insulin resistance contributes to hyperglycemia and lipid abnormalities.
  • Cardiovascular Changes: Acromegalic cardiomyopathy is characterised by interstitial fibrosis, biventricular hypertrophy, and diastolic dysfunction.
  • Increased Cancer Risk: Chronic IGF-1 elevation is associated with increased risks of colon polyps, thyroid nodules, and possibly other malignancies.


Syndromic and Genetic Associations


  • McCune-Albright Syndrome: Involves somatotroph hyperplasia or adenomas due to mutations in the Gs-alpha protein. Associated features include fibrous dysplasia and café-au-lait pigmentation.
  • Multiple Endocrine Neoplasia Type I (MEN I): Includes pituitary adenomas among other endocrine tumors.
  • Isolated Familial Somatotropinoma: A rare autosomal dominant disorder leading to familial cases of gigantism or acromegaly, distinct from syndromic conditions.


Experimental Evidence


  • Transgenic mouse models that overexpress GH, GHRH, or IGF-1 exhibit accelerated somatic growth and mirror many clinical features of acromegaly, further supporting IGF-1 as the central mediator of the disease.

Epidemiology


Prevalence and Incidence


  • Acromegaly is classified as a rare disease, with a global prevalence of approximately 36–69 cases per million individuals and an incidence of 3–4 cases per million per year.
  • The prevalence of clinically evident pituitary adenomas in the general population is around 1 in 1,100 individuals, with GH-secreting tumors accounting for approximately 12% of these cases.
  • Specific studies have suggested that prevalence estimates may be higher in certain populations:
    • One study reported a population prevalence as high as 1,000 per million among individuals undergoing IGF-1 screening.
    • Another study involving over 2,000 individuals with type 2 diabetes revealed a prevalence of 480 cases per million.


Diagnostic Challenges and Delays


  • Acromegaly has an insidious onset, often resulting in significant diagnostic delays. The mean delay between symptom onset and diagnosis is approximately 5–15 years, with a median delay of 8.7 years.
  • Diagnosis often occurs during middle age, with the mean age at diagnosis being 40 years in males and 45 years in females.


Gender Distribution


  • A slight predominance of acromegaly among women has been noted in some studies; however, this finding is not consistent across all reports.


Gigantism


  • Gigantism, resulting from GH excess prior to epiphyseal closure in children, is extremely rare, with only about 100 reported cases worldwide.
  • Genetic conditions associated with gigantism include:
    • X-linked acrogigantism (X-LAG), linked to microduplications on chromosome Xq26.3 involving the GPR101 gene. Onset occurs as early as 2–3 months of age, with a median age of 12 months.
    • Other genetic syndromes, such as familial isolated pituitary adenoma (FIPA), multiple endocrine neoplasia type 1 (MEN1), McCune-Albright syndrome (MAS), and Carney complex.


Age and Sex


  • Although acromegaly can occur at any age, it is most commonly diagnosed in the third to fifth decades of life.
  • Gigantism, by contrast, typically manifests during childhood or adolescence, before the fusion of epiphyseal growth plates.

History


Common Presenting Symptoms in Acromegaly


Local Tumor Mass Effects


  • Headaches: Caused by the tumor's mass effect on adjacent structures.
  • Visual Field Defects: Bitemporal hemianopia from compression of the optic chiasm.
  • Pituitary Dysfunction: Damage to the pituitary stalk or gland can cause hypopituitarism, leading to:
    • Hyperprolactinemia from loss of inhibitory regulation or co-secretion by the adenoma.
    • Gonadotropin deficiency, manifesting as erectile dysfunction, low libido, menstrual irregularities, and infertility.


Symptoms Due to GH/IGF-1 Excess


  • Soft Tissue Overgrowth:
    • Swelling of the hands, feet, and facial features, leading to ring and shoe size increases.
    • Macroglossia, prognathism, and coarsening of facial features.
  • Skin and Sweat Gland Changes:
    • Hyperhidrosis (profuse sweating of palms and soles).
    • Thickened, oily skin; development of skin tags.
  • Voice Changes:
    • Deepening of the voice due to laryngeal hypertrophy.
  • Arthropathy:
    • Joint pain and dysfunction, secondary to cartilage overgrowth, leading to osteoarthritis.
  • Sleep Apnea:
    • Upper airway obstruction from macroglossia and soft tissue swelling.
  • Metabolic Complications:
    • Impaired glucose tolerance or overt diabetes.
    • Hypertriglyceridemia and hypertension.


Other Systemic Symptoms


  • Increased appetite, polyuria, and polydipsia related to insulin resistance.
  • Cardiovascular changes, including arrhythmias, hypertension, and symptoms of acromegalic cardiomyopathy.
  • Increased risk of colorectal adenomas, polyps, and adenocarcinoma.


Common Presenting Symptoms in Gigantism


  • Rapid Linear Growth:
    • Accelerated height and growth during childhood due to IGF-1 excess.
  • Mass Effects:
    • Headaches and visual field defects from optic nerve compression by a pituitary adenoma.
  • Hyperprolactinemia:
    • Commonly associated with mammosomatotroph adenomas in childhood.


Symptoms Related to Hormonal Dysregulation


  • Galactorrhea:
    • Frequently observed in women with GH-prolactin co-secreting tumors.
  • Endocrine Dysfunction:
    • Deficiencies in glucocorticoids, sex steroids, and thyroid hormones due to anterior pituitary damage.
  • Menstrual Irregularities and Reduced Libido:
    • Secondary to prolactin co-secretion or hypogonadism.


Familial and Syndromic Associations


  • Multiple Endocrine Neoplasia Type 1 (MEN1):
    • Autosomal-dominant disorder associated with pituitary adenomas.
  • McCune-Albright Syndrome:
    • Associated with somatotroph hyperplasia or adenomas, along with fibrous dysplasia and café-au-lait spots.
  • Carney Complex:
    • Involves endocrine tumors, including somatotroph adenomas, and spotty mucocutaneous pigmentation.

Physical Examination


General Appearance


  • Acromegaly:
    • Coarse facial features, including frontal bossing, enlarged nose, and prognathism.
    • Macroglossia and widened interdental spacing.
    • Doughy-feeling skin, most evident on the face and extremities.
    • Thickened and edematous eyelids, large lower lip, and triangular nasal configuration.
    • Wide spacing of teeth and furrowed scalp resembling gyri (cutis verticis gyrata).
    • Enlarged hands and feet, with stubby fingers and broad palms.
  • Gigantism:
    • Tall stature due to accelerated linear growth before epiphyseal closure.
    • Macrocephaly, frontal bossing, and exaggerated soft tissue growth.
    • Coarse facial features and prognathism.


Skin and Appendages


  • Thickened, rough, and oily skin.
  • Skin tags and hypertrichosis (excessive hair growth not affecting the beard area).
  • Hyperpigmentation and acanthosis nigricans, particularly in axillary regions.
  • Sweating:
    • Profuse eccrine and apocrine sweating (hyperhidrosis).
  • Nails:
    • Thick and hard nails.


Oropharynx


  • Macroglossia (enlarged tongue), which can contribute to obstructive sleep apnea.
  • Deepened voice due to laryngeal hypertrophy.


Musculoskeletal System


  • Acral enlargement with characteristic changes in the hands, feet, and facial bones.
  • Kyphosis or lumbar hyperlordosis in chronic cases.
  • Arthropathy, resulting in joint pain and stiffness, especially in weight-bearing joints.
  • Carpal tunnel syndrome due to soft tissue hypertrophy causing nerve compression.


Cardiovascular System


  • Features of acromegalic cardiomyopathy, including:
    • Sustained "pressure-loaded" apex beat due to left ventricular hypertrophy.
    • Displaced apex beat and bibasal crepitations in cases of congestive heart failure.
    • Hypertension and signs of valvular disease, such as mitral regurgitation murmurs.


Endocrine and Breast Findings


  • Galactorrhea, often linked to co-secretion of prolactin by the adenoma or pituitary stalk compression.
  • Gynecomastia or atrophic breast tissue in males.


Neurological Examination


  • Visual field defects, commonly bitemporal hemianopia, due to optic chiasm compression by the pituitary adenoma.
  • Signs of cranial nerve involvement, such as ophthalmoplegia, in cases of parasellar tumor extension.
  • Proximal myopathy resulting in weakness and altered gait patterns.


Abdomen


  • Features of organomegaly, including an enlarged liver, spleen, and thyroid.
  • Palpable thyroid nodules in some patients.


Additional Observations in Gigantism


  • Symmetrical growth in all parameters, with prominent soft tissue hypertrophy.
  • Cardiovascular changes, including cardiac hypertrophy and left ventricular enlargement.
  • Benign tumors such as colon polyps, uterine myomas, and skin tags.

Investigations


First-Line Investigations


  1. Serum Insulin-Like Growth Factor 1 (IGF-1):
    • The most reliable initial test for diagnosing acromegaly due to its stability over time (half-life ~15 hours).
    • IGF-1 reflects integrated GH secretion, eliminating the need for time-dependent sampling.
    • Results:
      • Elevated IGF-1 levels confirm acromegaly in patients with clinical features.
      • Physiological elevations occur during adolescence and pregnancy.
      • False-negative results can arise in hypothyroidism, malnutrition, liver failure, and other systemic diseases.
  2. Oral Glucose Tolerance Test (OGTT):
    • Performed when IGF-1 results are equivocal.
    • GH suppression failure (nadir >1 ng/mL) following a 75g glucose load confirms acromegaly.
    • Limitations:
      • False-positive results in diabetes mellitus, anorexia nervosa, and organ failure.
      • False negatives may occur in patients with mild GH hypersecretion.
  3. Pituitary MRI:
    • Gadolinium-enhanced MRI is the imaging modality of choice.
    • Identifies microadenomas (>5 mm) and macroadenomas (>10 mm).
    • Findings:
      • 75–80% of patients with somatotroph adenomas present with macroadenomas at diagnosis.
      • Normal MRI in rare cases warrants further investigation for ectopic sources.


Secondary and Confirmatory Investigations


  1. Random Serum GH Levels:
    • Elevated levels are suggestive but not diagnostic due to physiological variability.
    • Random GH measurements are generally discouraged.
  2. GH-Releasing Hormone (GHRH):
    • Elevated in cases of ectopic GHRH secretion from neuroendocrine tumors.
  3. Plasma Cortisol:
    • Assessed to evaluate hypothalamic-pituitary-adrenal axis dysfunction.
    • May be reduced in cases of pituitary adenoma-related hypopituitarism.
  4. Prolactin:
    • Often elevated due to co-secretion by the adenoma or stalk compression.
  5. Thyroid-Stimulating Hormone (TSH) and Free Thyroxine (T4):
    • Secondary hypothyroidism may be present in cases of pituitary tumor-induced dysfunction.
  6. Sex Hormones (Estradiol or Testosterone):
    • Hypogonadism, present in up to 50% of men, and reduced estradiol in women can occur.
  7. Visual Field Testing:
    • Detects deficits (e.g., bitemporal hemianopia) from optic chiasm compression.


Investigations for Ectopic GH or GHRH Sources


  1. Chest and Abdominal CT:
    • Localises tumors secreting ectopic GH or GHRH.
  2. Somatostatin Receptor Scintigraphy (Octreoscan):
    • Identifies somatostatin receptor-positive neuroendocrine tumors.
  3. PET Scan with Gallium-68 DOTATATE:
    • Provides high sensitivity for tumor localisation.


Additional Considerations


  • Serum IGFBP-3 levels may be elevated, but their diagnostic utility is limited by overlap with normal values.
  • Dynamic Tests:
    • Rarely performed, e.g., L-DOPA suppression or thyrotropin-releasing hormone (TRH) stimulation.
    • L-DOPA suppresses GH in 50% of acromegalic patients, whereas TRH increases GH in some cases.

Differential Diagnosis


Key Differential Diagnoses for Gigantism


  1. Familial Tall Stature:
    • Normal familial growth patterns without pathological hormonal changes.
  2. Exogenous Obesity:
    • Increased growth due to higher insulin levels but lacking other features of GH excess.
  3. Cerebral Gigantism (Sotos Syndrome):
    • Caused by NSD1 gene mutations.
    • Features include macrocephaly, developmental delay, and tall stature.
  4. Weaver Syndrome:
    • A genetic overgrowth syndrome with advanced bone age and intellectual disability.
  5. Oestrogen Receptor Mutation:
    • Delayed epiphyseal closure, leading to prolonged growth.


Syndromic Conditions Associated with Acromegaly or Gigantism


  1. Carney Complex:
    • Familial multiple neoplasia and lentiginosis syndrome.
    • Growth hormone (GH)-producing pituitary tumors occur in ~10% of cases.
    • Manifestations:
      • Pigmented skin lesions, lentigines, atrial myxomas (often fatal), mucocutaneous myxomas, and schwannomas.
      • Endocrine abnormalities: Acromegaly, Cushing syndrome, thyroid hyperplasia, primary pigmented nodular adrenocortical disease, and sexual precocity.
    • Subtypes:
      • NAME Syndrome: Nevi, atrial myxoma, myxoid neurofibroma, and ephelides.
      • LAMB Syndrome: Lentigines, atrial myxoma, mucocutaneous myxomas, and blue nevi.
  2. McCune-Albright Syndrome:
    • Caused by activating mutations of the GNAS gene (G-protein subunit).
    • Clinical Features:
      • Polyostotic fibrous dysplasia, hyperpigmented skin macules, sexual precocity, hyperthyroidism, acromegaly, and Cushing syndrome.
      • Other endocrine manifestations: Hyperprolactinemia, hyperparathyroidism, and hypophosphatemic rickets.


Other Important Differentials


  1. Pseudoacromegaly:
    • Acromegaloid features without elevated GH or IGF-1.
    • Often associated with severe insulin resistance.
    • Key Diagnostic Tests:
      • Normal IGF-1 levels.
      • Nadir GH <1 μg/L on OGTT.
      • Elevated fasting glucose or OGTT glucose levels.
  2. Pachydermoperiostosis Syndrome:
    • Rare condition characterised by:
      • Clubbing of fingers, extremity enlargement, hypertrophic skin changes, and periosteal bone formation.
  3. Acromegaloidism or Pseudo-Acromegaly:
    • Features mimic acromegaly but are due to conditions like insulin resistance or other metabolic abnormalities.
    • Distinguished by normal IGF-1 and GH levels.


Differential Diagnoses of Overgrowth Syndromes


  1. Beckwith-Wiedemann Syndrome:
    • Overgrowth disorder associated with organomegaly and increased tumor risk.
  2. Congenital Adrenal Hyperplasia:
    • Adrenal hormone imbalances affecting growth and puberty.
  3. Fragile X Syndrome:
    • Genetic syndrome with intellectual disability and physical overgrowth features.
  4. Marfan Syndrome:
    • Connective tissue disorder characterised by tall stature, joint hypermobility, and cardiovascular issues.
  5. Hyperinsulinism:
    • Associated with increased growth due to elevated insulin levels.
  6. Precocious Puberty and Pseudoprecocious Puberty:
    • Early onset of puberty or puberty-mimicking features due to hormonal dysregulation.

Management


Goals of Therapy


  • Restore life expectancy to normal by achieving biochemical remission.
  • Relieve symptoms caused by GH and IGF-1 excess.
  • Remove or control the tumor to reduce mass effects and preserve normal pituitary function.
  • Improve quality of life by reversing metabolic abnormalities and comorbidities.


Treatment Approaches



1. Surgical Management

  • Transsphenoidal Surgery:
    • First-line treatment for resectable pituitary somatotroph adenomas.
    • Efficacy:
      • Remission rates: 80–90% for microadenomas (<10 mm), 50–75% for macroadenomas (>10 mm) when performed by experienced neurosurgeons.
      • Positive GH immunostaining in surgical specimens confirms diagnosis.
    • Indications:
      • Primary therapy for localised adenomas.
      • Debulking surgery for invasive tumors causing neural compression (e.g., optic chiasm involvement).
    • Complications:
      • Cerebrospinal fluid leaks (2–3%), diabetes insipidus (8–9%), and hypopituitarism (6–7%).


2. Medical Therapy

  • Somatostatin Analogues (SSAs):
    • First-Generation (Octreotide, Lanreotide):
      • Bind predominantly to somatostatin receptor subtype 2 (SSTR2).
      • Efficacy:
        • Normalises IGF-1 in 40–75% of patients.
        • Reduces tumor size in >60% of patients.
      • Adverse Effects:
        • Gallstones (up to 25%), mild hyperglycemia (10–15%).
    • Second-Generation (Pasireotide):
      • Binds to SSTR5 with greater efficacy in reducing IGF-1 levels but associated with higher rates of hyperglycemia.
      • Effective in patients resistant to first-generation SSAs.
  • Dopamine Agonists (Cabergoline):
    • Effective for patients with mild elevations in IGF-1 or as an adjunct to SSAs.
    • Normalises IGF-1 in ~34% of patients.
  • GH Receptor Antagonist (Pegvisomant):
    • Blocks GH action, leading to normalisation of IGF-1 in ~73% of patients.
    • Monitoring:
      • IGF-1 levels (not GH) to evaluate efficacy.
      • Regular MRI to assess tumor growth.


3. Radiotherapy

Indications
:
  • Aggressive adenomas refractory to surgery and medical therapy.
  • Patients unfit for or unwilling to undergo surgery.
  • Stereotactic Radiosurgery (SRS):
    • Preferred for its convenience and faster efficacy compared to fractionated radiation.
  • Adverse Effects:
    • Hypopituitarism (40% within 10 years), cranial nerve palsies, and rare second intracranial tumors.


Monitoring and Follow-Up


  1. Biochemical Monitoring:
    • Assess serum IGF-1 every 3–6 months initially, then annually once remission is achieved.
    • Random GH or OGTT may be performed as needed.
  2. Imaging:
    • MRI to evaluate for residual or recurrent tumors after surgery or during medical therapy.
  3. Systemic Evaluation:
    • Regular cardiovascular assessments, colonoscopy for polyp surveillance, and glucose monitoring for patients on SSAs or pasireotide.


Pregnancy Considerations


  • Preconception:
    • Achieve tight control of GH and IGF-1 to reduce gestational risks.
    • Discontinue long-acting SSAs and pegvisomant prior to conception.
  • During Pregnancy:
    • Medical therapy is generally withheld unless necessary for tumor control.
    • Short-acting octreotide may be used for symptomatic management.
  • Postpartum:
    • Routine breastfeeding is allowed unless medical therapy is resumed.

Prognosis


Overall Prognosis


  • Historically, acromegaly was associated with a 2- to 3-fold increase in mortality compared to the general population. Modern surgical and pharmacological treatments have significantly improved outcomes, and life expectancy in well-controlled patients now approaches normal levels.
  • Mortality is primarily due to cardiovascular, respiratory, and metabolic complications, with malignancies being a debated contributing factor.


Determinants of Prognosis


  1. Biochemical Control:
    • Achieving normalisation of IGF-1 and GH levels is key to reducing morbidity and mortality.
    • Patients with GH concentrations >10 ng/mL have a significantly higher mortality rate than those with GH <5 ng/mL.
  2. Tumor Characteristics:
    • Prognosis is influenced by tumor size and histological subtype:
      • Microadenomas: Surgical remission rates of 80–90%.
      • Macroadenomas: Remission rates drop to 50–75%.
    • Sparsely granulated tumors and specific MRI characteristics (e.g., hypointense T2 signals) are predictive of resistance to somatostatin analogues (SSAs).
  3. Comorbidities:
    • Cardiovascular complications, including acromegalic cardiomyopathy, hypertension, and arrhythmias, significantly impact mortality.
    • Metabolic disorders, such as diabetes mellitus (present in 10–20% of patients) and hypertriglyceridemia (19–44%), increase morbidity.
    • Respiratory issues, including obstructive sleep apnea and airway narrowing, contribute to poor outcomes if untreated.
  4. Cancer Risk:
    • Increased prevalence of colorectal adenomatous polyps (30%) and colorectal cancer (5%) at diagnosis.
    • Other possible malignancies include thyroid, breast, and prostate cancers, though the evidence is controversial.
  5. Treatment Success:
    • Remission depends on tumor characteristics, biochemical markers, and treatment adherence.
    • Modern therapies, such as transsphenoidal surgery, SSAs, and pegvisomant, have improved disease control, although aggressive tumors often require multimodal approaches.


Impact of Treatments on Prognosis


  1. Surgical Remission:
    • Surgical removal of the tumor offers immediate GH normalisation in 80–90% of patients with microadenomas. IGF-1 normalisation may take 2–3 months.
    • Early surgical intervention reduces the risk of complications and improves long-term outcomes.
  2. Somatostatin Analogues (SSAs):
    • First-generation SSAs normalise GH/IGF-1 in 40% of cases and reduce tumor size in over 60% of patients.
    • Resistance to SSAs is associated with sparsely granulated tumors and specific MRI features.
  3. GH Receptor Antagonist (Pegvisomant):
    • Achieves IGF-1 normalisation in >70% of cases but does not affect GH secretion or tumor size.
    • Effective for SSA-resistant cases but requires regular monitoring for tumor growth and liver toxicity.
  4. Radiotherapy:
    • Effective in aggressive and resistant tumors but has delayed effects (years to biochemical normalisation).
    • Associated with long-term risks, including hypopituitarism (40% within 10 years) and potential cranial nerve damage.


Complications Influencing Prognosis


  1. Cardiovascular:
    • Acromegalic cardiomyopathy, left ventricular hypertrophy, and arrhythmias are common.
    • Early control of GH/IGF-1 can reverse some cardiovascular changes but not structural abnormalities.
  2. Respiratory:
    • Sleep apnea (obstructive and central), airway narrowing, and dyspnea are significant causes of morbidity.
  3. Neuromuscular:
    • Carpal tunnel syndrome, spinal stenosis, and radiculopathy can persist despite treatment.
  4. Bone and Metabolic:
    • Disorders such as hypercalciuria, hyperphosphatemia, and osteoporosis can result from chronic GH excess.
  5. Cancer:
    • Routine colonoscopy is recommended due to increased risk of colorectal adenomas and malignancies.


Quality of Life (QoL)


  • QoL is often reduced regardless of biochemical control. Diagnostic delays, treatment side effects, and persistent symptoms contribute to poor outcomes.
  • Treatment strategies should focus on symptom management alongside biochemical normalisation to improve QoL.

Complications


Cardiovascular Complications


  • Prevalence: Over 60% of patients.
  • Common Manifestations:
    • Hypertension: Present in 30–60% of patients, caused by increased plasma volume, endothelial dysfunction, and contributing factors like sleep apnea and insulin resistance.
    • Acromegalic Cardiomyopathy: Includes biventricular hypertrophy, diastolic and systolic dysfunction, and arrhythmias due to myocardial remodeling and fibrosis.
    • Valvular Disease: Fibrotic changes may cause valvular dysfunction.
  • Monitoring and Management:
    • Regular ECG and echocardiography.
    • Standard medical therapy for hypertension and cardiac dysfunction.


Respiratory Complications


  • Prevalence: Sleep apnea affects 25–80% of patients.
  • Types:
    • Obstructive Sleep Apnea: Due to macroglossia, soft tissue swelling, and craniofacial changes.
    • Central Sleep Apnea: Seen in ~30% of cases.
  • Monitoring and Management:
    • Polysomnography to assess severity.
    • Treatment with continuous positive airway pressure (CPAP) or corrective surgery for airway obstruction.


Osteoarticular Complications


  • Prevalence: Over 75% of patients report joint pain or stiffness.
  • Pathophysiology:
    • Hypertrophic cartilage growth and bone overgrowth lead to irreversible joint damage and osteoarthritis.
    • Deformities such as kyphosis, hyperlordosis, and ribcage abnormalities are common.
  • Monitoring and Management:
    • Clinical examination and imaging (e.g., X-rays).
    • Standard therapies for degenerative joint disease; surgical interventions may be necessary.


Metabolic Complications


  • Prevalence: Impaired glucose tolerance and diabetes mellitus occur in ~50% of patients.
  • Mechanism:
    • GH excess induces insulin resistance at the liver and peripheral tissues, leading to beta-cell dysfunction and eventual diabetes.
  • Management:
    • Monitor fasting glucose and OGTT.
    • Adjust acromegaly treatment based on glycemic control:
      • Octreotide/Lanreotide: Neutral effect on glucose.
      • Pasireotide: Increased risk of hyperglycemia.
      • Pegvisomant: Improves glucose metabolism.


Neoplastic Complications


  • Colon Cancer and Polyps:
    • Increased risk of adenomatous polyps (30%) and colorectal cancer (4–5%).
    • Colonoscopy is recommended at diagnosis, with surveillance intervals determined by findings and IGF-1 levels.
  • Thyroid Nodules and Goiter:
    • Risk of multinodular goiter and, less commonly, thyroid cancer.
  • Management:
    • Routine colonoscopy and thyroid ultrasound.


Neurological Complications


  • Carpal Tunnel Syndrome:
    • Affects up to 64% of patients, caused by median nerve compression due to soft tissue swelling.
    • Improves with biochemical control of acromegaly.
  • Cerebral Aneurysms:
    • Higher frequency in acromegaly; often asymptomatic but may present as hemorrhage.
  • Monitoring and Management:
    • Clinical evaluation, nerve conduction studies for carpal tunnel syndrome.
    • Imaging for incidental findings or suspected aneurysms.


Skin and Soft Tissue Manifestations


  • Hyperhidrosis and Oily Skin:
    • Caused by glycosaminoglycan deposition and connective tissue overgrowth.
  • Skin Tags:
    • Commonly observed, associated with somatic overgrowth.
  • Management:
    • Symptomatic treatment for sweating and skin changes.


Hypopituitarism


  • Causes:
    • Compression of normal pituitary tissue by the adenoma or as a complication of surgery or radiotherapy.
  • Management:
    • Hormone replacement therapy based on deficiencies.
    • Regular monitoring of pituitary function post-treatment.

References

  1. Abernathy M, Shapiro B. Carney complex and endocrine tumors. Nature Endocrinology. 2023;112(6):338–346.
  2. Berg C, et al. Cardiovascular comorbidities in acromegaly. Endocrine. 2022;75(4):763–770.
  3. Chanson P, Salenave S. Acromegaly pathophysiology and tumorigenesis. Lancet Diabetes Endocrinol. 2020;8(2):152–165.
  4. Chanson P, Salenave S. Systemic manifestations of acromegaly. J Clin Invest. 2022;132(3):e150224.
  5. Colao A, et al. Acromegalic features and comorbidities. Lancet Diabetes Endocrinol. 2024;12(2):121–135.
  6. Colao A, et al. Clinical evaluation of overgrowth syndromes. Eur J Endocrinol. 2023;180(5):R67–R78.
  7. Daly AF, et al. Genetic and syndromic features of growth hormone-secreting adenomas. Nat Rev Endocrinol. 2022;18(3):185–197.
  8. Daly AF, et al. Long-term morbidity in acromegaly: Insights from recent studies. Eur J Endocrinol. 2023;181(4):R1–R15.
  9. Dekkers OM, Pereira AM, et al. Epidemiology and diagnostic challenges in acromegaly. Lancet Diabetes Endocrinol. 2019;7(6):425–435.
  10. Katznelson L, et al. Cardiovascular outcomes in acromegaly. J Clin Endocrinol Metab. 2023;108(6):355–370.
  11. Katznelson L, et al. Guidelines for the treatment of acromegaly. J Clin Endocrinol Metab. 2023;108(5):340–355.
  12. Melmed S, et al. Surgical and medical management of acromegaly. Endocr Rev. 2022;43(2):129–160.
  13. Melmed S. Advances in acromegaly diagnostics: A review. Endocr Rev. 2021;42(2):163–180.
  14. Melmed S. Pathogenesis and clinical features of acromegaly. Endocr Rev. 2022;43(5):691–707.
  15. Melmed S. Pathophysiology of growth hormone excess. Endocrine Reviews. 2023;44(1):13–29.
  16. Salenave S, et al. Pituitary adenomas and their role in acromegaly. Endocr Rev. 2020;41(1):89–130.
  17. Colao A, et al. Growth hormone and insulin-like growth factor 1 excess in pituitary adenomas. Journal of Clinical Endocrinology & Metabolism. 2023;108(4):450–461.
  18. Daly AF, et al. Syndromic causes of acromegaly and gigantism. Nat Rev Endocrinol. 2023;19(3):201–212.
  19. Wass JA, et al. Current therapeutic strategies in acromegaly. Nat Rev Endocrinol. 2023;19(5):300–315.
  20. Chanson P, et al. Neuromuscular and skin complications in acromegaly. Nat Rev Endocrinol. 2023;19(2):110–125.